Windward Bio Announces Closing Of $251.2 Million Initial Public Offering And Concurrent Private Placement, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
In addition to the common shares sold in the initial public offering, Windward announced the closing of the concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million. The sale of the common shares and the pre-funded warrants was not registered under the Securities Act of 1933, as amended (the“Securities Act”).
Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank acted as joint book-running managers for the offering.
The initial public offering was made only by means of a prospectus. Copies of the final prospectus related to the initial public offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at...; TD Securities (USA) LLC, Attn: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at...; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or by email at... or UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010, by email at....
A registration statement relating to the shares sold in the initial public offering was declared effective by the Securities and Exchange Commission (the "SEC") on November 12, 2026. Copies of the registration statement can be accessed by visiting the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Windward Bio Group AG
Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD. Windward's second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study.
For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment